Physician profile
Naresh Bellam
NPI 1538373907
$16,609.29
in general payments reported to CMS, 2019-2025
75 companies · $3,409 in 2025
The $3,409 reported for 2025 was more than what 76% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,777 · 2020: $495 · 2021: $670 · 2022: $2,846 · 2023: $3,147 · 2024: $3,265 · 2025: $3,409.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,596 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $225.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,595.85 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $225.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,815.23 | 2019-2025 | |
| Pfizer INC. | $1,180.93 | 2019-2025 | |
| Janssen Biotech, INC. | $858.96 | 2019-2025 | Darzalex, Tecvayli, Talvey |
| Genentech USA, INC. | $822.62 | 2019-2025 | Tecentriq, Polivy, Lunsumio |
| Astrazeneca Pharmaceuticals LP | $777.52 | 2019-2025 | Lynparza, Calquence, Imfinzi |
| Celgene Corporation | $672.69 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| E.R. Squibb & Sons, L.L.C. | $648.35 | 2019-2025 | Opdivo, Opdualag, Eliquis |
| Abbvie INC. | $646.48 | 2019-2025 | Venclexta, Dalvance |
| Amgen INC. | $636.72 | 2019-2023 | Prolia, Evenity, Kyprolis |
| Merck Sharp & Dohme LLC | $623.26 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Eisai INC. | $405.05 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $367.33 | 2019-2025 | Libtayo |
| Incyte Corporation | $360.75 | 2019-2025 | Jakafi, Monjuvi, Zynyz |
| Takeda Pharmaceuticals U.S.A., INC. | $354.26 | 2019-2025 | Ninlaro, Fruzaqla, Iclusig |
| Daiichi Sankyo INC. | $337.10 | 2019-2025 | Enhertu, Injectafer |
Show all 75 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $327.76 | 2019-2025 | Padcev, Xtandi, Vyloy |
| Lilly USA, LLC | $315.92 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Genzyme Corporation | $302.00 | 2019-2025 | |
| Glaxosmithkline, LLC. | $284.97 | 2019-2025 | Jemperli, Ojjaara, Zejula |
| Array Biopharma INC | $271.88 | 2019-2025 | Mektovi, Braftovi, Tukysa |
| Seagen INC. | $248.58 | 2021-2023 | Tukysa, Padcev, Adcetris |
| Alexion Pharmaceuticals, INC. | $230.00 | 2019-2024 | Ultomiris |
| Exelixis INC. | $227.28 | 2019-2025 | Cabometyx |
| Bayer Healthcare Pharmaceuticals INC. | $221.97 | 2019-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $175.70 | 2020-2023 | Imbruvica, Epkinly |
| Karyopharm Therapeutics INC. | $158.64 | 2021-2025 | Xpovio |
| Kite Pharma, INC. | $158.13 | 2022-2025 | Yescarta |
| Puma Biotechnology, INC. | $156.01 | 2019-2025 | |
| Stemline Therapeutics INC. | $151.78 | 2020-2025 | Orserdu |
| Sumitomo Pharma America, INC. | $150.88 | 2023-2025 | Orgovyx |
| Gilead Sciences, INC. | $148.02 | 2019-2025 | Trodelvy |
| Aveo Pharmaceuticals, INC. | $146.62 | 2021-2025 | Fotivda |
| Deciphera Pharmaceuticals INC. | $134.19 | 2023-2025 | Qinlock, Romvimza, Tgct |
| Rigel Pharmaceuticals, INC. | $132.22 | 2019-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Coherus Oncology, INC. | $130.06 | 2022-2025 | Loqtorzi |
| Myriad Genetic Laboratories, INC. | $110.55 | 2023-2024 | Bracanalysis Cdx, Myrisk |
| Genmab U.S., INC. | $110.15 | 2023-2025 | Epkinly |
| Pharmaessentia USA Corporation | $109.79 | 2022-2025 | Besremi |
| Adaptive Biotechnologies Corporation | $109.08 | 2022-2024 | Clonoseq |
| Servier Pharmaceuticals LLC | $97.12 | 2024-2025 | |
| Beone Medicines USA, INC. | $93.05 | 2025 | Brukinsa, Tevimbra |
| Beigene USA, INC. | $91.70 | 2022-2025 | Brukinsa |
| Progenics Pharmaceuticals, INC. | $85.91 | 2022-2024 | Pylarify |
| Sobi, INC | $85.85 | 2023-2025 | |
| Tesaro, INC. | $82.06 | 2019 | |
| Global Blood Therapeutics, INC. | $74.91 | 2021-2022 | |
| Taiho Oncology, INC. | $60.30 | 2023-2025 | |
| Pharmacosmos Therapeutics INC. | $58.21 | 2023-2025 | Monoferric |
| Jazz Pharmaceuticals INC. | $56.20 | 2019-2022 | |
| Dova Pharmaceuticals | $54.83 | 2019-2020 | |
| Kyowa Kirin, INC. | $52.44 | 2019-2025 | Poteligeo |
| Springworks Therapeutics, INC. | $52.17 | 2025 | Ogsiveo |
| Blue Earth Diagnostics | $45.78 | 2024 | |
| Janssen Pharmaceuticals, INC | $45.21 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.08 | 2019-2025 | |
| Adc Therapeutics America, INC. | $42.24 | 2022-2023 | |
| Verastem, INC. | $41.54 | 2019-2020 | |
| Clovis Oncology, INC. | $40.40 | 2019 | |
| Emd Serono, INC. | $35.44 | 2024-2025 | |
| Forte Bio-Pharma LLC | $35.27 | 2022-2023 | Prolate, Nalocet |
| Apellis Pharmaceuticals, INC. | $33.92 | 2023-2024 | Empaveli |
| Morphosys, US INC. | $31.32 | 2022-2023 | Monjuvi |
| Mirati Therapeutics, INC. | $29.79 | 2023-2024 | Krazati |
| Myovant Sciences INC. | $26.19 | 2021 | |
| Blueprint Medicines Corporation | $25.60 | 2023 | Ayvakit |
| Epizyme, INC. | $23.00 | 2021 | |
| Aurobindo Pharma USA, INC. | $19.28 | 2019 | |
| Immunogen, INC. | $18.87 | 2023 | Elahere |
| Geron Corporation | $18.64 | 2025 | Rytelo |
| Lexicon Pharmaceuticals, INC. | $16.56 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $15.87 | 2020 | |
| Agios Pharmaceuticals, INC. | $15.61 | 2025 | Pyrukynd |
| Helsinn Therapeutics (U.S.), INC. | $14.96 | 2021 | |
| Caris Mpi, INC. | $14.77 | 2025 | Mi Cancer Seek |
| Boston Scientific Corporation | $11.77 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Naresh Bellam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.